Paladin Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$292K Hold
317
0.22% 64
2025
Q4
$341K Hold
317
0.25% 61
2025
Q3
$242K Hold
317
0.19% 69
2025
Q2
$247K Sell
317
-126
-28% -$97.9K 0.19% 74
2025
Q1
$366K Sell
443
-147
-25% -$122K 0.29% 58
2024
Q4
$455K Hold
590
0.35% 52
2024
Q3
$523K Hold
590
0.39% 48
2024
Q2
$539K Hold
590
0.42% 47
2024
Q1
$449K Hold
590
0.35% 52
2023
Q4
$344K Hold
590
0.28% 59
2023
Q3
$317K Hold
590
0.27% 63
2023
Q2
$277K Hold
590
0.22% 78
2023
Q1
$203K Buy
+590
New +$199K 0.17% 96
2022
Q2
Sell
-590
Closed -$177K 413
2022
Q1
$172K Buy
+590
New +$152K 0.14% 102

Other funds holding LLY

Paladin Advisory Group's LLY Position: Q1 2026 in Review

Paladin Advisory Group held its Eli Lilly (LLY) position steady in Q1 2026 at 317 shares worth $292K. The position accounts for 0.22% of the portfolio, ranked #64.

Paladin Advisory Group first reported a position in LLY in Q1 2022 and has held it in 14 quarters since. The position peaked at $539K in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Paladin Advisory Group held 317 shares of Eli Lilly worth $292K as of Q1 2026.
  • Paladin Advisory Group left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.22% of Paladin Advisory Group's portfolio in Q1 2026, its #64 holding.
  • Paladin Advisory Group first reported a position in Eli Lilly in Q1 2022 and has held it in 14 quarters since.
  • Paladin Advisory Group's Eli Lilly position peaked at $539K in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Paladin Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.